PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1901507
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1901507
Febrile Neutropenia Market, By Etiology, By Treatment, By Risk Factors, By Diagnostic Methods, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
Febrile Neutropenia Market size was valued at US$ 10,789.45 Million in 2024, expanding at a CAGR of 4.2% from 2025 to 2032.
Febrile neutropenia refers to a rapid-onset fever occurring in patients with abnormally low neutrophil counts, most commonly triggered by chemotherapy-induced bone marrow suppression. This condition represents a high-acuity medical emergency, demanding swift antimicrobial intervention to prevent severe infections and sepsis. The global market is gaining momentum as oncology caseloads rise and clinicians prioritize risk-stratified management protocols. Advancements in long-acting G-CSF formulations, rapid diagnostic panels, and infection-control algorithms are creating measurable shifts in clinical adoption. Yet, the landscape isn't all sunshine-elevated biologic drug prices, antimicrobial resistance, and reimbursement barriers continue to constrain equitable access, especially in resource-limited settings. Even so, the sector is ripe with opportunity as precision supportive-care models, point-of-care diagnostics, and AI-enabled infection-prediction tools move from pilot to mainstream. These innovations are poised to redefine febrile neutropenia management, setting the stage for safer, faster, and more cost-effective patient outcomes.
Febrile Neutropenia Market- Market Dynamics
Rising Global Burden of Cancer
The increasing global cancer burden is the most significant growth catalyst for the febrile neutropenia (FN) market, according to the World Health Organization (WHO), who states that the number of new cancer cases globally is expected to be a significant factor in the future due to increasing numbers of elderly individuals as well as individuals being exposed to additional risk factors (e.g. tobacco use; obesity and pollution). As a larger number of individuals undergo myelosuppressive chemotherapy and/or other types of aggressive cancer treatments, those individuals will experience a rise in incidence of neutropenia which leads to an increase in FN. Data indicates that febrile neutropenia occurs in as many as 30% of patients undergoing chemotherapy. The result is that as the amount of cancer patients continues to grow, the need for FN management solutions (including prophylactic treatments and rapid diagnostics) will grow along with it. Thus, the increase in cancer patient volumes is the main growth driver for the FN marketplace.
Febrile Neutropenia Market- Segmentation Analysis:
The Global Febrile Neutropenia Market is segmented on the basis of Etiology, Treatment, Risk Factors, Diagnostic Methods, and Region.
In terms of etiology, the febrile neutropenia market is divided into gram-negative bacteria, gram-positive bacteria, fungal infections, viral infections. In febrile neutropenia, gram-negative bacteria are considered one of the main clinical causes of this complication because of their high levels of virulence and increasing levels of resistance to antibiotics. Some of these organisms include Escherichia coli, Klebsiella, and Pseudomonas Aeruginosa and they continue to be the primary culprits. Gram-negative infections represent more than 40% of all healthcare-associated bloodstream infections according to data from the Center for Disease Control and Prevention, indicating the importance of managing these infections in patients with compromised immune systems (i.e., oncology patients). Therefore, their rapid advancement into sepsis coupled with an elevated risk of death from these infections warrants an immediate intervention with broad-spectrum antibiotics. The emergence of Beta-lactamase producing Extended Spectrum Beta-Lactamases (ESBLs) from Enterobacterales has added an additional level of complexity to the management of these infections. Therefore, there continues to be an increasing demand for the development of new antibiotics, rapid diagnostics, and the use of precision antimicrobial stewardship strategies in FN settings to help control the rise of these organisms.
Based on treatment, treatment of febrile neutropenia (FN) is almost entirely based on empirical antibiotic therapy because of the need to begin antimicrobials within 60 minutes of detecting fever, as outlined by the Infectious Disease Society of America (IDSA) and National Comprehensive Cancer Network (NCCN) guidelines. The so-called "golden hour" is imperative as FN patients can deteriorate rapidly into septic shock. The principal antibiotics utilized to treat FN patients include broad-spectrum B-lactams, carbapenems and anti-pseudomonal antibiotics. The global health threat posed by the rise in antimicrobial resistance has prompted hospitals to use combination therapy, extended-spectrum agents, and stewardship programs; this segment of care remains the mainstay of treatment for FN patients and will continue to evolve with ongoing developments in the availability of fast-acting intravenous (IV) formulations and high-sensitivity pathogen detection technologies.
Febrile Neutropenia Market- Geographical Insights
The febrile neutropenia treatment market in North America is high-value but mature. One of the reasons for this is because of the high levels of cancer being treated by this market; there's a very large number of cancer patients that are currently being treated in North America due to access to intensive chemotherapy. Additionally, there have been many cancer cases recorded in this geographical area; the United States, Canada, and Mexico have been identified as the leading nations in terms of new cancer cases in 2022 (approximately 2.9 million new cases). It is estimated that in 2024, there will be around 2.0 million new cases reported and over 611,000 deaths reported from cancer in the United States. Because these patients receive myelosuppressive therapies with the majority having supportive FN prophylaxis, there is a large pool of people at risk for febrile neutropenia. Given the establishment of hospitals with well-developed systems for treating FN, the strict adherence by healthcare providers to the IDSA and guidelines of the National Comprehensive Cancer Network (NCCN) for FN management, and the rapid acceptance of G-CSF biosimilars and broad-spectrum IV antibiotics, it is possible to print a high volume of cases, intervene early, and provide aggressive treatment to patients with febrile neutropenia. There are several factors impacting the treatment of febrile neutropenia in the United States, including; the rising trend of increasing antimicrobial resistance, the growing development of value-based care models, and the growing use of risk stratification pathways and outpatient management of FN in lower-risk patients utilizing rapid molecular diagnostics in emergency and oncology settings.
United States Febrile Neutropenia Market- Country Insights
The United States is the largest market in North America for medical products treating febrile neutropenia and continues to have one of the highest age-adjusted rates of cancer incidence (367 cases per 100,000) reported annually in the world. The fact that many patients receive intensive multi-drug chemotherapy, stem cell transplants, and new biologics/treatments with targeted anti-cancer drugs and immunotherapeutic regimens means there is a steady and persistent supply of patients who are at risk for developing febrile neutropenia. The American Cancer Society estimates that there will be approximately 2 million new cases of cancer and approximately 611,720 cancer deaths in the U.S. in 2024. Therefore, there continues to be a very strong demand for clear access to FN prophylactic therapies, appropriate empirical/antimicrobial therapy, and advanced supportive care to patients with FN. In addition to the above-mentioned benefits, the U.S. market is also experiencing high levels of reimbursement provided by health insurance companies for the use of G-CSF and expensive injectable products, as well as broad utilization of automated alert systems for sepsis detection and extensive development and use of antimicrobial stewardship programs. There are also cost and access issues, including disparities in access to care based on race, geographic location, and hospital-acquired infections, which are driving innovation and adoption of the use of outpatient FN management and oral step-down regimens, as well as the introduction of predictive analytics to triage higher-risk patients earlier in the treatment process.
Febrile Neutropenia Market- Competitive Landscape:
The landscape for Febrile Neutropenia is characterized by competition between a number of companies, including Amneal Pharmaceuticals, Inc., AstraZeneca, Aurobindo Pharma Limited, Bayer, BeyondSpring Inc., Biocon Biologics Ltd., Biogen, Bristol Myers Squibb, Celgene Cellerant Therapeutics, Coherus BioSciences, Eli Lilly, Fresenius Kabi, G1 Therapeutics, Gedeon Richter, GSK, Hanmi, Intas Pharmaceuticals, Johnson & Johnson, Kyowa Kirin, Merck & Co., Novartis AG, Partner Therapeutics, Pfizer Inc, Roche, Sanofi, Spectrum Pharmaceuticals, Teva, and Viatris Inc. The competition will primarily be around G-CSFs and G-CSF biosimilars, long acting pegfilgrastim (peg G-CSF or filgrastim) formulations and novel myeloprotective agents that are also part of general oncology portfolios. Biocon Biologics developed and commercialized pegfilgrastim biosimilar Fulphila with Viatris. Fulphila is approved in the U.S., European Union (EU), Canada, and other countries and is intended to decrease the length of time patients with neutropenia are at risk for febrile neutropenia, which provides an opportunity for biosimilars to create both price and access competition. Coherus expanded Pegfilgrastim franchise with UDENYCA and its on-body injection device, before choosing to sell the franchise to Intas/Accord while moving towards focus on Immuno-oncology. BeyondSpring advanced its myeloprotective candidate plinabulin, received Breakthrough Therapy designations for use in chemotherapy related neutropenia, but was ultimately issued an FDA complete response letter requesting additional data. G1 therapeutics' trilaciclib (COSELA) was the first myeloprotective therapy to have received FDA approval for prevention of chemotherapy associated myelosuppression. In this environment, the aforementioned larger pharmaceutical players (Pfizer, Merck, Novartis, Roche, Sanofi, J&J, AstraZeneca, Bayer, Lilly, and Teva) are incorporating FN-risk-reduction approaches into their Immunotherapy and Targeted Therapy regimens, pursuing alliances with biosimilar partners, and utilizing real-world evidence to maintain market shares in both mature and emerging markets, thereby making competition increasingly driven by the need for innovation and access..
Recent Developments:
In August 2025, Intas/Accord announced successful acquisition of UDENYCA, strengthening its biosimilar portfolio and positioning itself as a "global pegfilgrastim supplier." UDENYCA remains indicated to reduce infection incidence (i.e. FN risk) in non-myeloid cancer patients receiving myelosuppressive chemotherapy. The deal transferred not only the product, but also relevant Coherus teams responsible for sales, supply, manufacturing and quality.
In September 2025, Amgen (US) launched a new digital platform aimed at improving patient engagement and adherence to treatment protocols for febrile neutropenia. This initiative reflects Amgen's focus on digital transformation and its recognition of the importance of patient-centric approaches in enhancing treatment outcomes. By leveraging technology, Amgen is likely to strengthen its competitive edge and foster deeper connections with healthcare providers and patients alike.
In August 2025, Roche (CH) announced a significant collaboration with a leading biotechnology firm to develop a novel treatment for febrile neutropenia, which is expected to enter clinical trials in early 2026. This strategic move underscores Roche's commitment to innovation and its proactive approach to addressing unmet medical needs in the oncology space. By aligning with a biotechnology partner, Roche not only enhances its research capabilities but also positions itself to potentially capture a larger market share in the febrile neutropenia segment.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL FEBRILE NEUTROPENIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Amneal Pharmaceuticals, Inc.
- AstraZeneca
- Aurobindo Pharma Limited
- Bayer
- Beyond Spring Inc.
- Biocon Biologics Ltd.
- Biogen
- BristolMyers Squibb
- Celgene
- Cellerant Therapeutics, Inc.
- Coherus BioSciences, Inc.
- Eli Lilly and Company
- Fresenius Kabi
- G1 Therapeutics, Inc.
- Gedeon Richter Plc.
- GlaxoSmithKline
- Hanmi Pharmaceutical Co., Ltd.
- Intas Pharmaceuticals Ltd.
- Johnson & Johnson
- Kyowa Kirin Co., Ltd.
- Merck & Co., Inc.
- Novartis AG
- Partner Therapeutics, Inc.
- Pfizer Inc.
- Roche
- Sanofi
- Spectrum Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Others
GLOBAL FEBRILE NEUTROPENIA MARKET, BY ETIOLOGY- MARKET ANALYSIS, 2019 - 2032
- Gram-Negative Bacteria
- Gram-Positive Bacteria
- Fungal Infections
- Viral Infections
GLOBAL FEBRILE NEUTROPENIA MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032
- Empirical Antibiotic Therapy
- Targeted Antibiotic Therapy
- Supportive Care
GLOBAL FEBRILE NEUTROPENIA MARKET, BY RISK FACTORS- MARKET ANALYSIS, 2019 - 2032
- Chemotherapy-Induced Neutropenia
- Transplant-Related Neutropenia
- Genetic Disorders
GLOBAL FEBRILE NEUTROPENIA MARKET, BY DIAGNOSTIC METHODS- MARKET ANALYSIS, 2019 - 2032
- Blood Cultures
- Imaging Tests
- Bone Marrow Aspiration
GLOBAL FEBRILE NEUTROPENIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Table of Contents
1. Febrile Neutropenia Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Febrile Neutropenia Market Snippet by Etiology
- 2.1.2. Febrile Neutropenia Market Snippet by Treatment
- 2.1.3. Febrile Neutropenia Market Snippet by Risk Factors
- 2.1.4. Febrile Neutropenia Market Snippet by Diagnostic Methods
- 2.1.5. Febrile Neutropenia Market Snippet by Country
- 2.1.6. Febrile Neutropenia Market Snippet by Region
- 2.2. Competitive Insights
3. Febrile Neutropenia Key Market Trends
- 3.1. Febrile Neutropenia Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Febrile Neutropenia Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Febrile Neutropenia Market Opportunities
- 3.4. Febrile Neutropenia Market Future Trends
4. Febrile Neutropenia Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Febrile Neutropenia Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Febrile Neutropenia Market Landscape
- 6.1. Febrile Neutropenia Market Share Analysis, 2024
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Febrile Neutropenia Market - By Etiology
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Etiology, 2024 & 2032 (%)
- 7.1.2. Gram-Negative Bacteria
- 7.1.3. Gram-Positive Bacteria
- 7.1.4. Fungal Infections
- 7.1.5. Viral Infections
8. Febrile Neutropenia Market - By Treatment
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Treatment, 2024 & 2032 (%)
- 8.1.2. Empirical Antibiotic Therapy
- 8.1.3. Targeted Antibiotic Therapy
- 8.1.4. Supportive Care
9. Febrile Neutropenia Market - By Risk Factors
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Risk Factors, 2024 & 2032 (%)
- 9.1.2. Chemotherapy-Induced Neutropenia
- 9.1.3. Transplant-Related Neutropenia
- 9.1.4. Genetic Disorders
10. Febrile Neutropenia Market - By Diagnostic Methods
- 10.1. Overview
- 10.1.1. Segment Share Analysis, By Diagnostic Methods, 2024 & 2032 (%)
- 10.1.2. Blood Cultures
- 10.1.3. Imaging Tests
- 10.1.4. Bone Marrow Aspiration
11. Febrile Neutropenia Market- By Geography
- 11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
- 11.2. North America
- 11.2.1. Overview
- 11.2.2. Febrile Neutropenia Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
- 11.2.8.1. Overview
- 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.2.8.3. U.S. Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.2.8.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.2.8.5. U.S. Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.2.8.6. U.S. Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
- 11.2.9.1. Overview
- 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.2.9.3. Canada Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.2.9.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.2.9.5. Canada Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.2.9.6. Canada Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.3. Europe
- 11.3.1. Overview
- 11.3.2. Febrile Neutropenia Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
- 11.3.8.1. Overview
- 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.8.3. Germany Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.3.8.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.8.5. Germany Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.3.8.6. Germany Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.3.9. UK
- 11.3.9.1. Overview
- 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.9.3. UK Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.3.9.4. UK Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.9.5. UK Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.3.9.6. UK Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.3.10. France
- 11.3.10.1. Overview
- 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.10.3. France Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.3.10.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.10.5. France Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.3.10.6. France Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
- 11.3.11.1. Overview
- 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.11.3. Italy Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.3.11.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.11.5. Italy Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.3.11.6. Italy Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
- 11.3.12.1. Overview
- 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.12.3. Spain Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.3.12.4. Spain Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.12.5. Spain Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.3.12.6. Spain Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
- 11.3.13.1. Overview
- 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.13.3. The Netherlands Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.3.13.4. The Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.13.5. The Netherlands Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.3.13.6. The Netherlands Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
- 11.3.14.1. Overview
- 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.14.3. Sweden Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.3.14.4. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.14.5. Sweden Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.3.14.6. Sweden Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
- 11.3.15.1. Overview
- 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.15.3. Russia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.3.15.4. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.15.5. Russia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.3.15.6. Russia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
- 11.3.16.1. Overview
- 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.16.3. Poland Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.3.16.4. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.16.5. Poland Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.3.16.6. Poland Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
- 11.3.17.1. Overview
- 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.17.3. Rest of the Europe Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.3.17.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.3.17.5. Rest of the Europe Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.3.17.6. Rest of the Europe Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Febrile Neutropenia Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.4.8. China
- 11.4.8.1. Overview
- 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.8.3. China Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.4.8.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.8.5. China Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.4.8.6. China Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.4.9. India
- 11.4.9.1. Overview
- 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.9.3. India Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.4.9.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.9.5. India Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.4.9.6. India Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
- 11.4.10.1. Overview
- 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.10.3. Japan Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.10.5. Japan Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.4.10.6. Japan Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
- 11.4.11.1. Overview
- 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.11.3. South Korea Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.4.11.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.11.5. South Korea Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.4.11.6. South Korea Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
- 11.4.12.1. Overview
- 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.12.3. Australia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.4.12.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.12.5. Australia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.4.12.6. Australia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
- 11.4.13.1. Overview
- 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.13.3. Indonesia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.4.13.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.13.5. Indonesia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.4.13.6. Indonesia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
- 11.4.14.1. Overview
- 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.14.3. Thailand Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.4.14.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.14.5. Thailand Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.4.14.6. Thailand Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
- 11.4.15.1. Overview
- 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.15.3. Philippines Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.4.15.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.15.5. Philippines Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.4.15.6. Philippines Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
- 11.4.16.1. Overview
- 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.16.3. Rest of APAC Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.4.16.5. Rest of APAC Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.4.16.6. Rest of APAC Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Febrile Neutropenia Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
- 11.5.8.1. Overview
- 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.8.3. Brazil Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.5.8.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.5.8.5. Brazil Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.5.8.6. Brazil Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
- 11.5.9.1. Overview
- 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.9.3. Mexico Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.5.9.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.5.9.5. Mexico Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.5.9.6. Mexico Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
- 11.5.10.1. Overview
- 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.10.3. Argentina Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.5.10.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.5.10.5. Argentina Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.5.10.6. Argentina Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
- 11.5.11.1. Overview
- 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.11.3. Colombia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.5.11.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.5.11.5. Colombia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.5.11.6. Colombia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
- 11.5.12.1. Overview
- 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.12.3. Rest of LATAM Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.5.12.5. Rest of LATAM Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.5.12.6. Rest of LATAM Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Febrile Neutropenia Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
- 11.6.8.1. Overview
- 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.8.3. Saudi Arabia Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.8.5. Saudi Arabia Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.6.8.6. Saudi Arabia Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
- 11.6.9.1. Overview
- 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.9.3. United Arab Emirates Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.9.5. United Arab Emirates Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.6.9.6. United Arab Emirates Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
- 11.6.10.1. Overview
- 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.10.3. Israel Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.6.10.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.10.5. Israel Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.6.10.6. Israel Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
- 11.6.11.1. Overview
- 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.11.3. Turkey Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.6.11.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.11.5. Turkey Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.6.11.6. Turkey Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
- 11.6.12.1. Overview
- 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.12.3. Algeria Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.6.12.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.12.5. Algeria Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.6.12.6. Algeria Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
- 11.6.13.1. Overview
- 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.13.3. Egypt Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.6.13.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.13.5. Egypt Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.6.13.6. Egypt Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
- 11.6.14.1. Overview
- 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.14.3. Rest of MEA Market Size and Forecast, By Etiology, 2019 - 2032 (US$ Million)
- 11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
- 11.6.14.5. Rest of MEA Market Size and Forecast, By Risk Factors, 2019 - 2032 (US$ Million)
- 11.6.14.6. Rest of MEA Market Size and Forecast, By Diagnostic Methods, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Febrile Neutropenia Industry
- 12.1. Competitive Benchmarking
- 12.1.1. Competitive Dashboard
- 12.1.2. Competitive Positioning
- 12.2. Company Profiles
- 12.2.1. Amneal Pharmaceuticals, Inc.
- 12.2.2. AstraZeneca
- 12.2.3. Aurobindo Pharma Limited
- 12.2.4. Bayer
- 12.2.5. BeyondSpring Inc.
- 12.2.6. Biocon Biologics Ltd.
- 12.2.7. Biogen
- 12.2.8. BristolMyers Squibb
- 12.2.9. Celgene
- 12.2.10. Cellerant Therapeutics, Inc.
- 12.2.11. Coherus BioSciences, Inc.
- 12.2.12. Eli Lilly and Company
- 12.2.13. Fresenius Kabi
- 12.2.14. G1 Therapeutics, Inc.
- 12.2.15. Gedeon Richter Plc.
- 12.2.16. GlaxoSmithKline
- 12.2.17. Hanmi Pharmaceutical Co., Ltd.
- 12.2.18. Intas Pharmaceuticals Ltd.
- 12.2.19. Johnson Johnson
- 12.2.20. Kyowa Kirin Co., Ltd.
- 12.2.21. Merck & Co., Inc.
- 12.2.22. Novartis AG
- 12.2.23. Partner Therapeutics, Inc.
- 12.2.24. Pfizer Inc.
- 12.2.25. Roche
- 12.2.26. Sanofi
- 12.2.27. Spectrum Pharmaceuticals, Inc.
- 12.2.28. Teva Pharmaceutical Industries Ltd.
- 12.2.29. Viatris Inc.
- 12.2.30. Others
13. 360 Degree Analyst View
14. Appendix
- 14.1. Research Methodology
- 14.2. References
- 14.3. Abbreviations
- 14.4. Disclaimer
- 14.5. Contact Us
